Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMC-CS4 · 1 trial · 1 indication
Pharmacokinetics (PK) - Maximum concentration (Cmax) of IMC-CS4.
Pharmacokinetics - Minimum concentration (Cmin) of IMC-CS4.
Pharmacokinetics - Area Under the Curve (AUC) of IMC-CS4.
Pharmacokinetics - Volume of distribution at steady state (Vss) of IMC-CS4.
Pharmacokinetics -Clearance (Cl) of IMC-CS4.
| Arm | Type | Description |
|---|---|---|
| IMC-CS4 Weight Based Dosing | EXPERIMENTAL | Participants received 2.5 mg/kg once weekly (QW), 0.3 mg/kg QW, 0.6 mg/kg QW, 1.25 mg/kg every two weeks (Q2W) and1.25 mg/kg QW of IMC CS4 by intravenous infusion in Part A. |
| IMC-CS4 Non-Weight Based Dosing | EXPERIMENTAL | Participants received 100 mg QW, 100 mg QW on weeks 1, 2, 4 and 5 and 150 mg QW of IMC CS4 by intravenous infusion in Part B. |
| Name | Type | Description |
|---|---|---|
| IMC-CS4 | BIOLOGICAL | - |
Inclusion Criteria: * Subject has histologic or cytologic confirmation of advanced solid tumors that is refractory to standard therapy or for which no standard therapy is available * Subject has measurable or nonmeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) V...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
IMC-CS4 is an investigational monoclonal antibody being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed as a potential oncology therapy for patients with advanced solid tumors.
IMC-CS4 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational monoclonal antibody in oncology.
IMC-CS4 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and potential effectiveness in treating neoplasms.
IMC-CS4 has been studied in one clinical trial with the identifier NCT01346358, titled 'A Study of IMC-CS4 in Subjects With Advanced Solid Tumors.' This Phase 1 trial was completed and enrolled 52 participants in the United States, with a minimum age of 18 years.
Yes, IMC-CS4 is a monoclonal antibody, a type of biologic drug designed to bind to specific targets in the body. It is being investigated as a potential treatment for neoplasms, including advanced solid tumors, in the field of oncology.